Mod GRF 1-29 vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | Sermorelin |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
What They Have in Common
Both Mod GRF 1-29 and Sermorelin are commonly used for: